Status:

TERMINATED

PASCUAL (Prostate Assay Specific Clinical Utility at Launch) Study

Lead Sponsor:

MDx Health

Conditions:

Prostate Cancer

Eligibility:

MALE

40-75 years

Brief Summary

The main hypothesis of this study is to demonstrate that the use of the ConfirmMDx for Prostate Cancer test in previously biopsied patients improves urologists' patient management by reducing unnecess...

Detailed Description

The results of the study will reveal the clinical utility of this test by analyzing the physicians' use of negative or positive assays compared to patients managed using SOC methods without assay find...

Eligibility Criteria

Inclusion

  • Males aged 40 to 75 years old\* that underwent a previous cancer-negative prostate biopsy within 15 months and being considered for a repeat biopsy due to persistent or elevated cancer-risk factors
  • The previous negative prostate biopsy must have collected a minimum of 8 tissue cores and remaining FFPE tissue from all cores should be available for testing
  • Minimum tissue volume criteria of 20 microns of prostate biopsy core tissue should be available (40 microns preferable)
  • The presence of HGPIN (high-grade prostatic intraepithelial neoplasia), PIA (proliferative inflammatory atrophy), or glandular inflammation reported in the first biopsy histopathology report is acceptable for entry.

Exclusion

  • Prior diagnosis of prostate cancer or cellular atypia suspicious for cancer (ASAP) in a previous biopsy histology report.
  • Patients being managed by Active Surveillance for low stage prostate cancer
  • Men greater than 75 years old (generally not considered for repeat biopsy)
  • Most recent biopsy was a saturation biopsy (\> 24 tissue cores).
  • Tissue extracted using transurethral resection of the prostate (TURP) procedures rather than standard patterned biopsy core extraction.
  • Subjects who had been previously tested with ConfirmMDx.

Key Trial Info

Start Date :

September 1 2014

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

July 1 2018

Estimated Enrollment :

600 Patients enrolled

Trial Details

Trial ID

NCT02250313

Start Date

September 1 2014

End Date

July 1 2018

Last Update

July 26 2018

Active Locations (15)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (15 locations)

1

Urology Centers of Alabama

Homewood, Alabama, United States, 35209

2

Genesis Research LLC

San Diego, California, United States, 92123

3

Skyline Urology

Torrance, California, United States, 90505

4

Urology Center of Colorado

Denver, Colorado, United States, 80211